Association between Sarcopenia and Cognitive Functions in Older Individuals: A Cross-Sectional Study

Yigit, Busra; Öner, Can; Çeti̇n, Hüseyin; Şimşek, Engin Ersin

doi:10.4235/agmr.22.0027

Cited by 6 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 1,870 articles were initially evaluated. Eventually, 12 articles were included in our study [1][2][3][4][5][6][7][8][9][10][11][12] . The cumulative sample size across all the included studies amounted to 3,975 participants.…”

Section: Resultsmentioning

confidence: 99%

Prevalence and risk factors of Cognitive dysfunction -associated Sarcopenia：A systematic review and meta-analysis

wang,

Li,

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Even though sarcopenia and cognitive dysfunction(including mild cognitive impairment(MCI) and Alzheimer's disease (AD)) have an impact on each other, there is limited evidence regarding their correlation. Moreover, we currently lack information about the prevalence of cognitive dysfunction-related sarcopenia. Therefore, our objective was to conduct a systematic search to determine the prevalence of sarcopenia among individuals with cognitive disabilities. Additionally, we aimed to consolidate the overall prevalence rate of cognitive dysfunction-related sarcopenia by considering various factors such as age, country, and diagnostic criteria for sarcopenia. Methods To achieve this goal, we performed a thorough search of several databases, including Web of Science, PubMed, Embase, and Cochrane Library. The search concluded on December 31, 2022, with the inclusion of studies that reported the prevalence of sarcopenia in patients with cognitive dysfunction. We then conducted a meta-analysis using all the collected data. All the statistical analyses were carried out using the STATA 15.0 version software. Results A total of 1,870 articles were initially evaluated. Eventually, 12 articles were included in our study[1–12]. The cumulative sample size across all the included studies amounted to 3,975 participants. All 12 studies employed a cross-sectional design. Consequently, the combined prevalence rate was estimated to be 16.96% (with a 95% confidence interval of 0.122 to 0.278), displaying considerable heterogeneity (I2 = 98.17%).Regarding the sample of patients with MCI and sarcopenia, the prevalence of MCI patients with sarcopenia was found to be 10.24% (95%CI: 0.44 − 0.209). Moreover, within the sample of Alzheimer's disease (AD) patients with sarcopenia, the pooled prevalence of AD individuals with sarcopenia was determined to be 21.09% (95%CI: 0.131–0.299). Conclusions Our findings highlight the frequent occurrence of sarcopenia among individuals with cognitive dysfunction, and the prevalence of sarcopenia appears to vary according to the degree of cognitive dysfunction. These results hold significance as they provide valuable insights for researchers planning studies on sarcopenia within this population. Urgent attention should be given to conducting longitudinal studies that focus on sarcopenia and its outcomes in patients with cognitive dysfunction.

show abstract

Section: Resultsmentioning

confidence: 99%

Prevalence and risk factors of Cognitive dysfunction -associated Sarcopenia：A systematic review and meta-analysis

wang,

Li,

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In a similar vein, by conducting a secondary prevention study with 200 men aged 57.3±6.3 years, the work of Lutski et al [ 34 ] showed that subjects with two or more chronic conditions had a greater probability of experiencing subjective cognitive impairment over a 20-year follow-up period. Taken together, it appears that comorbidities result in physical and functional limitations or changes in brain macrostructure and microstructure, which have a negative impact on cognitive function [ 35 , 36 ] or vice versa [ 37 , 38 ]. As a result, a prospective cohort study will be required to determine the precise direction of the relationship between comorbidities and cognitive function.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, muscular strength is just as important as PA in reducing the physical- and mental-health burden of chronic disorders, such as depression [ 41 ] and cognitive decline [ 36 ]. For example, by examining data taken from the KLoSA 2006–2015 and 2014–2018, respectively, Jeong and Kim [ 42 ] and Lee et al [ 43 ] demonstrated that low handgrip strength was positively related to an elevated risk of cognitive impairment among older Korean adults.…”

Section: Discussionmentioning

confidence: 99%

Cognitive Function, and Its Relationships with Comorbidities, Physical Activity, and Muscular Strength in Korean Older Adults

Kim

2023

Behavioral Sciences

View full text Add to dashboard Cite

Background: Little is known regarding how much physical activity (PA) and lower-body muscle strength (LBMS) together can help to reduce the negative effect of comorbidities on cognitive function. This study examined the moderating effects of PA and LBMS in determining the relationship between comorbidities and cognitive function in older Korean adults. Materials and Methods: This is a population-based cross-sectional study. Data for this study were taken from the 2020 Korea Longitudinal Study on Aging (KLoSA) in South Korea using a computer-assisted personal interview. The 2020 KLoSA survey included a total of 10,097 older individuals aged 65 and older (6062 females and 4035 men). Comorbidities were determined based on physician-diagnosed chronic conditions. PA and LBMS were measured with a self-reported questionnaire and a sit-to-stand test, respectively. Cognitive function was assessed using the Korean version of the Mini-Mental Status Examination for dementia screening. Results: Multimorbidity was correlated with an increased risk (odds ratio, OR = 1.415, p < 0.001) of cognitive impairment. Insufficient PA and weak LBMS were correlated with an increased risk of cognitive impairment (OR = 1.340, p < 0.001; OR = 1.719, p < 0.001, respectively). Particularly, PA modulates the negative impact of comorbidities on cognitive function (β = −0.3833; 95% CI = −0.4743 to −0.2023) independent of all measured covariates. Weak LBMS was found to be an independent predictor of cognitive function (β = −2.5078, p < 0.001) regardless of comorbidities. Conclusions: The study findings suggest that a lifestyle intervention targeting regular PA and muscular fitness should be a therapeutic means against cognitive decline associated with normal aging and/or chronic diseases.

show abstract

“…The lowest global cognition score was linked to a type of fat called sarcopenic fat. A cross-sectional study by Yigit et al 26 ) on 201 participants aged >65 years in Istanbul reported significantly higher scores in older individuals with reduced cognitive function compared to the scores in participants with normal cognitive functions.…”

Section: Prevalence Of Sarcopenic Obesitymentioning

confidence: 98%

Prevalence of Sarcopenic Obesity in Various Comorbidities, Diagnostic Markers, and Therapeutic Approaches: A Review

Kumari

Khanna

2022

Ann Geriatr Med Res

View full text Add to dashboard Cite

The coexistence of sarcopenia and obesity characterizes sarcopenic obesity. In this condition, there is an imbalance between lean and fat mass amounts. It is a prevalent issue that is gaining prevalence among the elderly population. To evaluate the condition, allied health professionals may employ non-invasive diagnostic techniques, such as gait speed, skeletal muscle mass, and muscle strength. Nevertheless, early diagnosis and treatment of pathology are essential for preventing debilitating effects and providing the highest quality of care. This article reviews the prevalence of sarcopenic obesity in numerous medical conditions, such as cancer, arthritis, postoperative cases, diabetes mellitus, obesity, and metabolic syndrome. In addition, this paper aims to examine the available evidence regarding the prevalence of sarcopenic obesity in other conditions along with their diagnostic markers and therapeutic approaches.

show abstract

Association between Sarcopenia and Cognitive Functions in Older Individuals: A Cross-Sectional Study

Cited by 6 publications

References 28 publications

Prevalence and risk factors of Cognitive dysfunction -associated Sarcopenia：A systematic review and meta-analysis

Prevalence and risk factors of Cognitive dysfunction -associated Sarcopenia：A systematic review and meta-analysis

Cognitive Function, and Its Relationships with Comorbidities, Physical Activity, and Muscular Strength in Korean Older Adults

Prevalence of Sarcopenic Obesity in Various Comorbidities, Diagnostic Markers, and Therapeutic Approaches: A Review

Contact Info

Product

Resources

About